Biodesix, Inc. BDSX
10.12 USD +0.10 (+1.00%)
At closeNov 11, 2026, 4:19 PM EST
10.12 0.00 0.00%
After hours · Nov 11, 4:19 PM ET
9.68 Day range 11.30
5.46 52-week range 30.60
- YTD
- +48.82%
- 1 year
- +21.34%
News
globenewswire.com Biodesix (BDSX) Shares Plunge; Johnson Fistel's Colorado Office Initiates Investigation on Behalf of Investors SAN DIEGO, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a national shareholder rights law firm with an office in Denver, Colorado, has begun investigating potential securities claims on…
seekingalpha.com Biodesix, Inc. (BDSX) Presents at 2026 UBS Global Healthcare Conference Transcript Biodesix, Inc. (BDSX) Presents at 2026 UBS Global Healthcare Conference Transcript
globenewswire.com BIODESIX, INC. INVESTIGATION: BDSX Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Biodesix, Inc. (“Biodesix” or the “Company”) (NASDAQ: BDSX). The…
benzinga.com HC Wainwright & Co. Maintains Buy on Biodesix, Lowers Price Target to $34 HC Wainwright & Co. analyst Yi Chen maintains Biodesix (NASDAQ:BDSX) with a Buy and lowers the price target from $38 to $34.
globenewswire.com Biodesix to Showcase MRD Strategy at the Association for Molecular Pathology (AMP) 2026 Annual Meeting New data highlighting proprietary bioinformatics, ultrasensitive molecular detection, and collaborations with Bio-Rad Laboratories and Thermo Fisher Scientific to advance scalable MRD solutions for…
benzinga.com Lake Street Maintains Buy on Biodesix, Lowers Price Target to $30 Lake Street analyst Thomas Flaten maintains Biodesix (NASDAQ:BDSX) with a Buy and lowers the price target from $40 to $30.
globenewswire.com Biodesix (BDSX) Shares Plunge; Johnson Fistel's Colorado Office Initiates Investigation on Behalf of Investors SAN DIEGO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a national shareholder rights law firm with an office in Denver, Colorado, has begun investigating potential securities claims on…
zacks.com Champions Oncology vs. Biodesix: Which Oncology Stock Is a Better Buy? CSBR and BDSX ride on distinct oncology growth drivers, but which stock looks more compelling amid contrasting performance and valuations? Let's dive in.
benzinga.com Gold Down 1%; Charter Communications Shares Fall After Q3 Results U.S. stocks gained Friday, led by Nasdaq +1.5%, as jobs beat forecasts. Gogo and JFrog surged, while DraftKings and Biodesix plunged.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Obsidian Therapeutics (NASDAQ:OBX) stock increased by 27.7% to $12.26 during Friday's regular session. The company's market cap stands at $593.0 million. TransMedics Group (NASDAQ:TMDX)…
benzinga.com Nasdaq Jumps 400 Points; US Nonfarm Payrolls Top Estimates In October U.S. stocks were mixed: Nasdaq +1.75%, S&P +0.99%, Dow -0.21%, as October jobs beat forecasts; oil rose, while global markets mostly fell.
benzinga.com DraftKings Posts Downbeat Q3 Results, Joins Atlassian, Natera And Other Big Stocks Moving Lower In Friday’s Pre-Market Session Stock futures mixed as DraftKings plunged 21% after earnings missed estimates and FY26 guidance was cut; several other stocks also fell premarket.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Milestone Scientific (AMEX:MLSS) stock moved upwards by 19.5% to $0.36 during Friday's pre-market session. The company's market cap stands at $27.1 million. Eton Pharmaceuticals (NASDAQ:ETON)…
benzinga.com Why Cloudflare Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket Cloudflare jumped 14.6% after beating Q3 estimates; JFrog and Eton gained, while Site Centers and Biostem plunged premarket.
benzinga.com Biodesix Stock Crashes Nearly 30% After Q3 Revenue Miss, Slashes 2026 Outlook Biodesix shares fall after hours following third-quarter results and revised 2026 revenue guidance.
seekingalpha.com Biodesix, Inc. (BDSX) Q3 2026 Earnings Call Transcript Biodesix, Inc. (BDSX) Q3 2026 Earnings Call Transcript
zacks.com Biodesix, Inc. (BDSX) Reports Q3 Loss, Lags Revenue Estimates Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to a loss of $1.16 per share a year ago.
marketbeat.com What Biodesix (BDSX) Said on Its Q3 Earnings Call Biodesix NASDAQ: BDSX reported 10% revenue growth for the third quarter of 2026 but said results fell short of its expectations as a smaller-than-planned sales force, seasonal patterns in primary…
benzinga.com Biodesix Q3 2026 Earnings Call Transcript Biodesix (NASDAQ:BDSX) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Biodesix Lowers FY2026 Sales Guidance from $108.000M-$114.000M to $101.000M-$103.000M vs $111.817M Est Biodesix (NASDAQ:BDSX) lowers FY2026 sales outlook from $108.000 million-$114.000 million to $101.000 million-$103.000 million vs $111.817 million estimate.
globenewswire.com Biodesix Announces Third Quarter 2026 Results and Highlights Delivered total revenue of $24.0 million, an increase of 10% year over year Grew Diagnostic Testing revenue 16% year over year, with test volumes increasing 24% Maintained an 81% gross margin,…
globenewswire.com Biodesix to Participate in Upcoming Investor Conferences LOUISVILLE, Colo., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present…
zacks.com All You Need to Know About Biodesix (BDSX) Rating Upgrade to Buy Biodesix (BDSX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com Will Biodesix, Inc. (BDSX) Report Negative Earnings Next Week? What You Should Know Biodesix (BDSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
globenewswire.com Biodesix to Report Third Quarter 2026 Financial Results on November 5, 2026 LOUISVILLE, Colo., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the third…
benzinga.com Biodesix Announces That The American College Of Chest Physicians Has Published A New Framework For Clinical Practice, "Building A Lung Nodule Program: From Detection To Diagnosis." Biodesix, Inc (NASDAQ:BDSX), a leader in diagnostic solutions, today announced that the American College of Chest Physicians (CHEST) has published a new framework for clinical practice, "Building a…
globenewswire.com American College of Chest Physicians Publishes New Framework for Lung Nodule Programs Recommending Biomarkers for Risk Stratification New CHEST framework developed by a renowned multidisciplinary panel with expertise in building and managing lung nodule programs across diverse clinical practices New CHEST framework developed by a…- benzinga.com Biodesix Adds AI-Powered Imaging Test To Expand Lung Cancer Risk Screening Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostics solutions company, today announced the addition of Digital Diagnostics to its Lung Diagnostics strategy, establishing the foundation for a…
globenewswire.com Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers Partnership with Vanderbilt University and Vanderbilt Health accelerates development of the first radiomics-based test for lung nodule risk assessment Partnership with Vanderbilt University and…
benzinga.com TD Cowen Maintains Buy on Biodesix, Raises Price Target to $40 TD Cowen analyst Dan Brennan maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the price target from $30 to $40.
benzinga.com Biodesix Announces Multiple Presentations At CHEST 2026 Highlighting How Nodify Lung Testing Is Being Incorporated Into Real-World Lung Nodule Management The presentations build upon the strong evidence base with new use cases and clinical comparisons, illustrating how blood-based lung nodule risk assessment guides clinical decision-making, affects…
globenewswire.com Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026 New sponsored and independent research evaluates clinical utility, patient follow-up, and diagnostic test sequencing New sponsored and independent research evaluates clinical utility, patient…
zacks.com Biodesix Expands MRD Testing With Tumor-Informed and Tumor-Naive Tests BDSX advances two blood-based MRD programs with Bio-Rad and Thermo Fisher to broaden access to cancer monitoring.- benzinga.com Biodesix Announces Progress In Two Collaborative Programs For Tumor-informed And Tumor-naïve Molecular Residual Disease Solutions Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostics solutions company, today announced strategic progress in two collaborative programs for tumor-informed and tumor-naïve Molecular Residual Disease…
globenewswire.com Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring Biodesix-led tumor-informed and tumor-naïve programs draw on the company's bioinformatics and diagnostics test development expertise Biodesix-led tumor-informed and tumor-naïve programs draw on the…
globenewswire.com Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings Industry-leading QA/RA excellence accelerates patient access to Biodesix Lab testing, which helps improve overall outcomes for patients with lung nodules Industry-leading QA/RA excellence accelerates…- benzinga.com Canaccord Genuity Maintains Buy on Biodesix, Raises Price Target to $35 Canaccord Genuity analyst Kyle Mikson maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the price target from $27 to $35.
benzinga.com HC Wainwright & Co. Maintains Buy on Biodesix, Raises Price Target to $27 HC Wainwright & Co. analyst Yi Chen maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the price target from $26 to $27.- benzinga.com Biodesix Affirms FY2026 Sales Guidance of $108.000M-$114.000M vs $110.996M Est Biodesix (NASDAQ:BDSX) affirms FY2026 sales outlook from $108.000 million-$114.000 million to $108.000 million-$114.000 million vs $110.996 million estimate.
- benzinga.com Roth Capital Initiates Coverage On Biodesix with Buy Rating, Announces Price Target of $32 Roth Capital analyst Max Masucci initiates coverage on Biodesix (NASDAQ:BDSX) with a Buy rating and announces Price Target of $32.
- benzinga.com Canaccord Genuity Maintains Buy on Biodesix, Raises Price Target to $27 Canaccord Genuity analyst Kyle Mikson maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the price target from $22 to $27.
benzinga.com This ICU Medical Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Top Wall Street analysts changed outlook on top names. Find all rating changes on Benzinga's analyst ratings page. See analyst views on ICUI, BDSX,.- benzinga.com HC Wainwright & Co. Initiates Coverage On Biodesix with Buy Rating, Announces Price Target of $26 HC Wainwright & Co. analyst Yi Chen initiates coverage on Biodesix (NASDAQ:BDSX) with a Buy rating and announces Price Target of $26.
benzinga.com Canaccord Genuity Maintains Buy on Biodesix, Raises Price Target to $22 Canaccord Genuity analyst Kyle Mikson maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the price target from $20 to $22.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com Biodesix Q1 2026 Earnings Call: Complete Transcript - benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com Biodesix Raises FY2026 Sales Guidance from $106.000M-$112.000M to $108.000M-$114.000M vs $108.680M Est Biodesix (NASDAQ:BDSX) raises FY2026 sales outlook from $106.000 million-$112.000 million to $108.000 million-$114.000 million vs $108.680 million estimate.
- benzinga.com Biodesix Q1 EPS $(0.81) Beats $(1.12) Estimate, Sales $25.555M Beat $23.178M Estimate Biodesix (NASDAQ:BDSX) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(1.12) by 27.68 percent. This is a 49.38 percent increase over losses of $(1.60)…
benzinga.com Earnings Scheduled For May 4, 2026